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Abstract
Glucocorticoid (GC)-based therapies can cause insulin resistance (IR), glucose intolerance, hyperglycemia and, occasionally,
overt diabetes. Understanding the mechanisms behind these metabolic disorders could improve the management of
glucose homeostasis in patients undergoing GC treatment. For this purpose, adult rats were treated with a daily injection of
dexamethasone (1 mg/kg b.w., i.p.) (DEX) or saline as a control for 5 consecutive days. The DEX rats developed IR,
augmented glycemia, hyperinsulinemia and hyperglucagonemia. Treatment of the DEX rats with a glucagon receptor
antagonist normalized their blood glucose level. The characteristic inhibitory effect of glucose on glucagon secretion was
impaired in the islets of the DEX rats, while no direct effects were found on a-cells in islets that were incubated with DEX in
vitro. A higher proportion of docked secretory granules was found in the DEX a-cells as well as a trend towards increased a-
cell mass. Additionally, insulin secretion in the presence of glucagon was augmented in the islets of the DEX rats, which was
most likely due to their higher glucagon receptor content. We also found that the enzyme 11bHSD-1, which participates in
GC metabolism, contributed to the insulin hypersecretion in the DEX rats under basal glucose conditions. Altogether, we
showed that GC treatment induces hyperglucagonemia, which contributes to an imbalance in glucose homeostasis and
compensatory b-cell hypersecretion. This hyperglucagonemia may result from altered a-cell function and, likely, a-cell mass.
Additionally, blockage of the glucagon receptor seems to be effective in preventing the elevation in blood glucose levels
induced by GC administration.
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Introduction
Endogenous glucocorticoids (GCs), such as cortisol in humans
and corticosterone in rodents, play a key role in several
physiological functions like the regulation of glucose homeostasis
and nutrient metabolism [1]. Exogenous synthetic compounds
with GC activity, e.g., prednisolone and dexamethasone, are
broadly used for clinical purposes due to their anti-inflammatory,
anti-allergic and immunosuppressive effects [2]. GC therapy
provides beneficial effects for patients subjected to allotransplan-
tation and for patients with rheumatoid diseases, bowel diseases or
asthma, among other pathologies [2,3]. However, when admin-
istered in excess or for long periods, GCs can cause several adverse
effects [2,3]. Development of glucose intolerance, insulin resistance
(IR), hyperglycemia and dyslipidemia, especially among individ-
uals who are more susceptible to these disorders, are among the
diabetogenic effects of GC therapy [4–8].
Most of the adverse effects of GCs on metabolism are reversible
upon the discontinuation of GC treatment [7,9]. In addition,
intermittent prescriptions and/or low doses of GCs may attenuate
their diabetogenic effects [10]. However, patients receiving GCs
are commonly subjected to prolonged therapy that may culminate
in irreversible metabolic disorders, such as hyperglycemia or the
onset of type 2 diabetes mellitus (T2DM) [1,3]. Thus, glucose
homeostasis should be controlled in patients undergoing chronic
GC treatment or excessive acute exposure to steroid hormones.
A better understanding of the mechanisms involved in the
steroid-induced impairment of glucose homeostasis is necessary to
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generate strategies to diminish the side effects of GC therapy. In
this regard, GC-induced IR has been found to enhance b-cell
function and mass, inducing hyperinsulinemia as a compensatory
response to the increased insulin needs imposed by IR [6,11–13].
When this compensation is not sufficient, hyperglycemia may arise
[9,12]. Impaired pancreatic a-cell function has emerged as an
important factor in the etiology of the pathologies associated with
the deregulation of glucose homeostasis, such as obesity [14,15],
T2DM [16,17], and hypercortisolism [14]. In fact, a few animal
[18] and human [14,19] studies have reported that GC treatment
may induce altered glucagon levels. However, the mechanism by
which these changes occur has not been fully elucidated. Yet,
given that glucagon modulates insulin release [20,21], the
potential contribution of altered glucagon levels to the b-cell
hypersecretion and hyperinsulinemia of GC-treated subjects
remains to be investigated.
To elucidate the involvement of glucagon in the disruption of
glucose homeostasis and the insulin hypersecretion caused by GC
treatment, we treated rats with dexamethasone for five consecutive
days. These rats developed IR, hyperinsulinemia and mild
hyperglycemia. We demonstrate that glucagon plays a key role
in steroid-induced hyperglycemia, as alterations in pancreatic a-
cell function led to fasting and fed hyperglucagonemia. Interest-
ingly, the specific blockade of glucagon receptors normalized the
GC-induced hyperglycemia in these rats. Additionally, we
observed that hyperglucagonemia and 11bHSD-1 pre-receptor
GC metabolism contribute to insulin hypersecretion.
Methods
Animals
The experiments were performed with 3-month-old, male
Wistar rats. The rats were obtained from the animal breeding
centers of Miguel Herna´ndez University and the Federal
University of Santa Catarina. They were kept at 21uC61uC on
a 12 h light/dark cycle (lights on 06:00 – lights off 18:00) and had
access to commercial standard chow and water ad libitum.
According to national regulations, the experiments were approved
by the Committees for Ethics in Animal Experimentation of
Miguel Herna´ndez University (approval ID: IB-IQM-001-12) and
Federal University of Santa Catarina (approval ID: PP00782).
Dexamethasone treatment, plasma measurements and
intraperitoneal glucose tolerance test [ipGTT)
Dexamethasone-treated rats (DEX) received one daily intra-
peritoneal (i.p.) injection (07:30–08:30 h) of dexamethasone
(1 mg/kg b.w.) for 5 consecutive days according to previous
studies [7,13], whereas control rats (CTL) received saline (1 ml of
0.9% NaCl/kg b.w.). Blood was collected from the tails of fasted
(12–14 h) and fed rats, and the glucose levels were measured with
a glucometer (Accu-Check Performa, Roche Diagnostics GmbH,
Mannhein, Germany). Euthanasia was performed by CO2
exposure followed by decapitation, and the trunk blood was
collected in tubes containing anticoagulant and aprotinin (Sigma,
Madrid, Spain) for subsequent insulin or glucagon determination.
Plasma was obtained by centrifugation for 10 min at 1,0006g and
4uC, and either insulin or glucagon were measured using a Coat-a-
count RIA kit (DPC, Los Angeles, CA, USA) or ELISA (Gentaur,
San Jose, CA, USA), respectively, according to the manufacturer’s
instructions [13,22,23]. The homeostatic model assessment
(HOMA), triacylclycerol and glucose index (TyG index) and
ipGTT were performed as described previously [24]. A separate
group of rats received a daily i.p. injection of des-His1-(Glu9]-
glucagon (1–29) amide (1 mmol/l.kg21 b.w.) (Tocris Bioscience, IO
Centre Bristol, UK), a selective antagonist of the glucagon
receptor, during the last 3 days of dexamethasone administration.
This antagonist has been proven to be efficient in lowering of
hyperglycemia induced by endogenous glucagon in different
animal models like streptozotocin diabetic rats [25,26].
Islet isolation and determination of hormonal secretion
Islets were isolated by collagenase digestion as previously
described [7]. The total islet insulin and glucagon contents were
measured by RIA or ELISA after overnight extraction of the islets
in acid-ethanol lysis buffer as previously described [23]. The
protocol used to determine insulin secretion was described in detail
previously [7,13]. Briefly, after the islets were isolated, groups of
five islets were incubated for 1 h at 37uC in 1 ml of a Krebs-
bicarbonate buffer solution (pH 7.4) containing 5.6 mmol/l
glucose supplemented with 0.05% bovine serum albumin and
equilibrated with a mixture of 95% O2 : 5% CO2. The medium
was then replaced with 1 ml of fresh buffer and incubated for an
additional hour. Then, the supernatant was collected and stored at
280uC for the subsequent measurement of insulin. To determine
glucagon secretion, groups of twelve islets were incubated for 1 h
at 37uC in 0.5 ml of a Krebs-bicarbonate buffer solution
containing 8.3 mmol/l glucose. The medium was then replaced
with 0.4 ml of fresh buffer containing the solutions indicated in
each experiment and incubated for 1 h [23]. At the end of the
incubation period, the supernatants were stored at 280uC for the
subsequent measurement of glucagon content by ELISA.
Quantitative morphometric analysis of the endocrine
pancreas
For the morphometric analysis, 6–7 pancreases from each group
were excised and processed as previously published [12], except
that 4% phosphate-buffered paraformaldehyde was used as a
fixative solution. The cellular distribution of glucagon was
analyzed by immunostaining with a polyclonal anti-glucagon
antibody (sc7779; Santa Cruz Biotechnology, Heidelberg, Ger-
many). The a-cell mass was determined for each immunostained
pancreas section by point counting morphometry as previously
described [23], with minor modifications. Briefly, each section was
systematically scored with a grid of 196 points (final magnification
6200) using the image processing and analysis software ImageJ
(available at http://rsbweb.nih.gov/ij/). The numbers of inter-
cepts over a-cells, endocrine non-a-cells, exocrine pancreatic
tissue, and non-exocrine pancreatic tissue were counted. The a-
cell relative volume was calculated by dividing the intercepts over
a-cells by the intercepts over the total pancreatic tissue; the a-cell
mass was then estimated by multiplying the a-cell relative volume
by the total pancreas weight. A total of 1765 and 1588 fields were
counted for pancreases from control and malnourished mice,
respectively.
Transmission electron microscopy [TEM) and granule
morphometry
Pools of isolated islets were processed for transmission electron
microscopy as described previously [13]. Observations were made
and electron micrographs were prepared using a Zeiss Leo 906
transmission electron microscope operated at 80 kV. To deter-
mine the cytoplasmic granule density, all granules were counted
and divided by the cytoplasmic area. The percentage of granules
docked at the plasma membrane was defined as the percentage of
granules that were in contact with the plasma membrane in each
median section [13]. The granules were only examined in a-cells
containing a well-defined nucleus in the median section.
Pancreatic Alpha-Cell Function in DEX Rats
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Distribution of the glucagon receptor and 11bHSD-1 in
the endocrine pancreas
Pancreases from each group were excised and processed as
described previously [27]. Sections were cut at a thickness of 5 mm,
dewaxed in xylene, and rehydrated in a graded ethanol series. The
sections were incubated in PBS containing 3% BSA for 1 h at
room temperature to block non-specific binding and then with the
following antibodies in PBS containing 3% BSA overnight at 4uC:
anti-glucagon receptor (1:100, bs-3945R; Bioss, Woburn, MA),
anti-insulin (1:100, I2018; Sigma, Madrid, Spain), anti-glucagon
(1:100, G2654; Sigma, Madrid, Spain), and anti 11b-HSD1 (1:50,
sc-20175; Santa Cruz Biotechnology). After washing, the sections
were incubated with the corresponding secondary antibodies
(1:1000, Alexa Fluor; Molecular Probes, Leiden, The Netherlands)
for 1 h at room temperature. Hoechst 33342 (Life Technologies,
Madrid, Spain) was used for nuclear staining. Images were
captured using a Leica TCS SP2 AOBS spectral confocal
microscope.
Protein extraction and immunoblotting
Protein extraction and immunoblotting were performed as
previously described [7,8]. Pools of isolated islets were homoge-
nized in ice-cold cell lysis buffer (Cell Signaling, Danvers, MA,
USA). The protein concentration in the total cell lysate was
determined by the Bradford protein assay (Bio-Rad, Hercules, CA,
USA). The same amount of islet protein (50 mg) was used for each
experiment. Experiments were performed at least six times using
different samples (each sample consisted of islets obtained from
one rat). After 2 h of blocking at RT, the membranes containing
the islet protein lysates were washed with TBST and incubated
overnight with the appropriate primary antibodies. The polyclonal
anti-glucagon receptor (sc66912) and polyclonal anti-11bHSD-1
(sc20175) antibodies were purchased from Santa Cruz Biotech-
nology, and the polyclonal anti-b actin antibody (#A2066) was
obtained from Sigma. After washing with TBST, the membranes
were incubated with the appropriate secondary antibody. Anti-
body binding was detected using the Clarity Western ECL
Substrate (Bio-Rad).
Data Analysis
The results are expressed as the mean 6 SEM of the indicated
number (n) of experiments. Statistical comparisons between the
data from the DEX and CTL groups were performed using the
unpaired Student’s t-test, with Welch correction when necessary.
For unpaired groups, one-way analysis of variance (ANOVA)
followed by the Tukey or Student-Newman-Keuls post test was used
for multiple comparisons of parametric data. When necessary, the
nonparametric Kruskal-Wallis test followed by the Dunn post test
was applied. Significance was set at p,0.05.
Results
Hyperglucagonemia is involved in the increased plasma
glucose levels of DEX rats
As expected [13], GC administration caused an increase in the
blood glucose concentration in both fasted (<22%) and fed
(<21%) rats compared with the controls (Figs. 1A, G and H) as
well as 8.5- and 2.0-fold increases in the plasma insulin
concentration during the fasted and fed states, respectively
(Fig. 1B). The plasma glucagon levels were also higher in fasted
(27%) and fed (53%) rats treated with dexamethasone than rats
treated with saline (Fig. 1C). The saline-treated rats had a higher
plasma insulin to glucagon ratio from the fasted state to the fed
state (Fig. 1D). Conversely, the plasma insulin to glucagon ratio
was markedly elevated in fasted DEX rats and did not differ
significantly from the fasted state to the fed state, further pointing
to an impairment in the bihormonal control of glucose (Fig. 1D).
In accordance with previous studies showing that GC induces
insulin resistance and glucose intolerance [6,8,24], the HOMA
and the TyG indexes and ipGTTs revealed a significant reduction
in insulin sensitivity and glucose tolerance in the DEX rats
compared with the control rats (Figs. 1E, F, and G, respectively).
To analyze whether the elevated plasma glucagon levels were
involved in the increased blood glucose concentration observed in
the DEX rats, we co-treated the DEX rats with the glucagon
receptor antagonist des-His1-(Glu9]-glucagon (1–29) amide
[25,26]. Under these conditions, we observed a partial attenuation
of the GC-induced increase in blood glucose in the DEX rats
during fasting (Fig. 1H) and a total blockage during the fed state
(Fig. 1I). In summary, we found an increase in blood glucose and
plasma insulin after GC treatment, which is in agreement with
previous reports [7]. The hyperglucagonemia that was observed in
both energetic states, the unaltered insulin/glucagon ratio from
the fasted state to the fed state, and the findings from our glucagon
receptor antagonist experiment suggest an important role for
glucagon in the glucose homeostasis imbalance resulting from
chronic GC administration.
The inhibition of glucagon secretion by pancreatic a-cells
in response to glucose is impaired in DEX rats
Considering the higher plasma glucagon levels found in the
DEX rats, we next evaluated the pancreatic a-cell response to
glucose in these animals using an ex vivo glucagon secretion
protocol. Figure 2A shows the level of glucagon secreted after 1 h
of incubation with 0.5 mmol/l or 11.1 mmol/l glucose. While
11.1 mmol/l inhibited glucagon secretion compared with 0.5 mM
glucose in the control rats, as has been previously shown [17], this
high level of glucose did not significantly affect the GC-treated rats
(Fig. 2A). Actually, the islets of the DEX rats secreted a
significantly higher amount of glucagon (57%) upon incubation
with 11.1 mmol/l glucose compared with the CTL islets. The
values of glucagon secretion expressed in absolute terms (ng/l)
further emphasize this difference between CTL and DEX rats
after incubation with 11.1 mmol/l glucose (Table 1). There was no
difference in the total islet glucagon content between the DEX and
CTL groups (Fig. 2B), suggesting that the differences in secretion
were not related to glucagon synthesis. To assess whether
dexamethasone exerted any direct effect on glucose-stimulated
glucagon secretion, we performed an in vitro experiment with an
acute 3-h preincubation of the islets with 1 mmol/l dexamethasone
before the 1-h incubation period with glucose in the absence of
dexamethasone. As observed in Figure 2C and Table 1, there were
no differences in the glucagon response to the low or high glucose
concentration between the DEX and saline-treated groups nor in
the total islet glucagon content (Fig. 2D). Thus, the inhibitory
effect of glucose on a-cell function is impaired in DEX rats, which
may account for the augmented glucagon levels observed after GC
treatment. In addition, this response does not seem to be related to
increased islet glucagon content and/or direct dexamethasone
effects.
The pancreatic a-cell mass in DEX-treated rats
Changes in the pancreatic a-cell mass may contribute to
alterations in the plasma glucagon level. In Figure 3A, we show a
panoramic view of several pancreas sections. Note the typical
hypertrophied islets in the DEX pancreas sections (arrows in
Fig. 3A) as a result of b-cell hyperplasia and hypertrophy [12].
Pancreatic Alpha-Cell Function in DEX Rats
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There was no apparent change in the proportion of a-cells per islet
between the treatment groups (22.361.7% and 21.462.7% for the
CTL and DEX rats, respectively). The islet density (number per
pancreas area) was significantly higher in pancreas from DEX rats
(p,0.05) (Fig. 3B). The relative and absolute a-cell mass was larger
in the DEX pancreases compared with the CTL pancreases (69%
and 28%, respectively), although these differences were not
statistically significant (Figs. 3C and D). When the absolute a-
cell mass was normalized to the body weight, we found a 51%
increase in the DEX group compared with the control group
(p = 0.07) (Fig. 3E). The pancreas masses values were 1.160.05 g
for CTL and 0.960.04 g for DEX rats, whereas the average body
weights were 32865 and 28764 g for CTL and DEX,
respectively. As expected [7,12], the non-a-cell mass, which is
predominantly comprised of b-cells, was higher in the DEX rats
compared with the controls (Figure S1). Thus, in addition to the
alterations in a-cell function, an increased a-cell mass, although
not statistically significant, might play a role in the excessive
glucagon levels found in the GC-treated rats.
The a-cell ultrastructure indicates an increase in cell
function and docked glucagon granules at the cell
membrane in DEX rats
Considering our evidence of increased a-cell function in the
DEX rats, we next investigated the ultrastructural characteristics
and organelle distribution of the a-cells. The main ultrastructural
change observed in the DEX rat a-cells was an enlargement of the
cisternal space in the Golgi complex (Fig. 4A). Quantification of
the total granule number in the a-cells per median section revealed
no change between the treatment groups (Fig. 4B). The glucagon
granule density in the cytosol was not altered between the DEX
and CTL rats (data not shown). However, the proportion of
glucagon granules docked to the cell membrane was significantly
increased in the a-cells in the DEX rats compared with controls
(Fig. 4C). These data support the enhancement of a-cell secretory
function in DEX rats.
Figure 1. Hyperglucagonemia is involved in the hyperglycemia of DEX rats. A: Blood glucose, B: plasma insulin, C: plasma glucagon, and D:
plasma insulin to glucagon ratio in fasted (12–14 h) and fed DEX and CTL rats. E: HOMA index, F: TyG index and G: ipGTT in fasted (12–14 h) DEX and
CTL rats. H: Fasted and I: fed blood glucose in rats receiving 1 mmol/l.kg21 of des-His1-(Glu9]-glucagon (1–29) amide from the third day to the last day
of dexamethasone administration. Data are the mean 6 SEM. n=10 in A to G. n= 7 in H and I. * p,0.05, ** p,0.01, *** p,0.001 vs. CTL. { p,0.05,
{{{ p,0.001 vs. fasted in A, B, C and D. # p,0.05 vs. DEX. HOMA, homeostatic model assessment; ipGTT, intraperitoneal glucose tolerance test.
doi:10.1371/journal.pone.0093531.g001
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Glucagon is involved in the hypersecretion of insulin by
the islets of DEX rats
Considering the marked increase in the plasma insulin
concentration under fasting conditions in DEX rats and that
insulin secretion may be positively modulated by glucagon action
[20,21], we next investigated whether glucagon exerts a higher
impact on the b-cell response to basal glucose concentrations. In
Figure 5A, we show the insulin response to 5.6 mmol/l glucose
alone or in combination with 1 mmol/l glucagon or 5 mmol/l
forskolin. Incubation of islets from CTL rats in the presence of
glucagon or forskolin did not result in a significant increase in
insulin secretion (Figure 5A and Table 1). In contrast, for the islets
of DEX rats, the insulin response in the presence of glucagon or
forskolin was significantly higher compared to incubation with
5.6 mmol/l glucose alone (Figure 5A and Table 2). This insulin
hypersecretion in DEX animals seems not to be related with
increased insulin biosynthesis since the total islet insulin content
was slightly decreased in DEX rats (2.4860.05 vs.
2.860.06 nmol/l.islet21 for DEX and CTL groups, respectively).
Thus, glucagon seems to exert a positive modulatory effect on
insulin secretion under basal glucose concentrations in DEX rats,
and this action may be involved in the fasting hyperinsulinemia
observed after GC treatment.
Figure 2. The inhibition of glucagon secretion by pancreatic a-cells in response to glucose is impaired in DEX rats. A: Glucagon
secretion in response to 0.5 mmol/l or 11.1 mmol/l glucose in isolated islets from DEX and CTL rats (n=10 wells). B: Total islet glucagon content
(n=10). C: In vitro glucagon secretion in response to 0.5 mmol/l or 11.1 mmol/l glucose in isolated islets that were pre-incubated for 3 h with
8.3 mmol glucose with or without 1 mmol/l dexamethasone (n=10 wells). D: Total islet glucagon content (n= 10). Data are the mean 6 SEM.
* p,0.05 vs. CTL. { p,0.05 vs. 0.5 mmol/l glucose. G, glucose.
doi:10.1371/journal.pone.0093531.g002
Table 1. Glucagon secretion (ng/l) per islet in response to
low or high glucose in isolated islets.
Ex vivo In vitro
0.5 mmol/l 11.1 mmol/l 0.5 mmol/l 11.1 mmol/l
CTL 21.062.7 13.061.7{ 18.562.4 13.561.1{
DEX 27.862.9 21.462.2{* 20.661.2 14.361.6{
Data are expressed as mean 6 SEM (n=10 wells).
* p,0.05 vs. CTL and
{p,0.05 vs. 0.5 mmol/l glucose.
doi:10.1371/journal.pone.0093531.t001
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Western blot analysis revealed that the DEX rats had a higher
(38%) level of glucagon receptor in their islets (Fig. 5B), further
supporting the stimulatory effect of glucagon on insulin secretion
upon GC treatment. Immunocytochemistry of pancreas sections
showed the localization of the glucagon receptor in the pancreatic
b-cells (as well as in a-cells) in both groups (Fig. 5C).
Involvement of 11bHSD-1 in insulin secretion
Because inactive endogenous 11-DHC is locally converted to
active corticosterone (CORT) inside islets by 11bHSD-1 and
because CORT modulates insulin secretion, we next evaluated the
effect of 11-DHC on b-cell function. As expected [7,11], insulin
secretion in response to 5.6 mmol/l or 16.7 mmol/l glucose was
significantly higher in the islets of the DEX rats compared to those
of controls (Figs. 6A and B). Incubation with 11-DHC and
5.6 mmol/l glucose showed no impact on insulin secretion in the
CTL rats but resulted in higher insulin release in the DEX rats.
The insulin increase observed in the presence of 11-DHC was
totally abrogated by co-incubation with the 11bHSD-1 antagonist
carbenoxolone (5 mmol/l). The effect of 11-DHC in the presence
of 5.6 mmol/l glucose was not observed with islets challenged with
11-DHC and 16.7 mmol/l glucose for both treatment groups
(Fig. 6B), most likely because this glucose concentration is close to
the maximal stimulation of insulin release. Altogether, these data
provide evidence for a role of pre-receptor glucocorticoid
metabolism in insulin secretion under basal physiological condi-
tions that supports insulin hypersecretion and fasting hyperinsu-
linemia.
No differences were observed in the 11bHSD-1 protein content
between the DEX and CTL groups (Fig. 7A). In contrast with a
previous report showing that 11bHSD-1 is predominantly located
in glucagon-containing cells [28], we did not observe co-
localization of this enzyme with the peripheral pancreatic a-cells
(Fig. 7B). Instead, 11bHSD-1 was detected in the cells located in
the islet core, which were most likely b-cells.
Discussion
The classical adverse effects of GC therapy on glucose and
nutrient metabolism have been well known for decades. They
include glucose intolerance, peripheral insulin resistance, elevation
of the blood glucose levels, hyperinsulinemia, and alterations in
pancreatic b-cell function as our group and others have previously
reported [2,3,8,12,13]. The involvement of pancreatic a-cells in
this phenomenon has now emerged and raises new questions
related to the mechanisms underlying the imbalance in glucose
homeostasis caused by GC treatment. Here, we show for the first
time that glucose-intolerant and insulin-resistant rats created by
dexamethasone treatment exhibit 1) fasting and fed hypergluca-
gonemia, 2) an unaltered insulin/glucagon ratio from the fasted
state to the fed state, 3) impaired glucose-induced suppression of
glucagon secretion, 4) a trend to increase in a-cell mass, 5) an
Figure 3. The pancreatic a-cell mass in DEX rats. A: Panoramic and detailed view of DEX and CTL pancreas sections that were immunostained
for glucagon. B: Relative, C: absolute, and D: normalized a-cell mass in DEX and CTL rats. Data are the mean6 SEM (n= 6). Scale bars = 200, 50, 20 and
10 mm from the top to bottom images in A.
doi:10.1371/journal.pone.0093531.g003
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increase in the number of docked glucagon granules 6) augmented
islet glucagon receptor content as well as insulin secretion in
response to glucagon, and 7) enhanced insulin secretion in
response to 11-DHC under basal glucose conditions. The
significant reduction in the blood glucose levels in DEX rats by
treatment with a glucagon receptor antagonist points to the crucial
involvement of glucagon in the diabetogenic effects of GCs and
also indicates the antagonism of the glucagon receptor as a
potential therapeutic target to ameliorate the hyperglycemia
resulting from GC therapy.
In the 1970s, it was shown that non-obese human subjects
treated with dexamethasone developed high plasma glucose and
insulin levels along with increased fasting plasma glucagon levels
[14]. These individuals also showed a higher glucagon response to
alanine infusion compared to non-obese individuals. More
recently, altered fasting glucagon levels were observed in rhesus
macaques after dexamethasone treatment [18] and in rats by the
combination of exogenous corticosterone and high-fat diet [29].
Hyperglucagonemia and impaired a-cell function have been
linked to the etiology of both T1DM and T2DM [17]. Under
these pathological conditions, high glucose levels fail to suppress
glucagon release, favoring higher plasma glucagon levels, which
promote hepatic glucose output and contribute to hyperglycemia
[17]. In the present study, DEX rats exhibited high plasma
glucagon concentrations under both fasted and fed conditions.
Interestingly, their insulin/glucagon ratio did not increase from
the fasted state to the fed state, which may result in impaired
insulin suppressive effects and/or augmented hyperglycemic
actions of glucagon on the liver, as was previously suggested for
GC-treated humans [30]. In fact, the DEX rats are less insulin
sensitive as observed by the insulin tolerance test and basal adipose
tissue glycerol release as previously reported [7,8,24]. The absence
of increment in the insulin/glucagon ratio may also indicate a
relatively poor insulin secretion under feeding as confirmed by the
GTT experiments (Fig. 1G) in the DEX rats. The involvement of
glucagon in the high blood glucose levels of DEX rats was
supported by experiments with a glucagon receptor antagonist,
which fully prevented the elevation in the glycemic values of fed
DEX rats. Previous data with the same antagonist have showed its
inability to activate glycogenolysis as well as its ability to lowers the
hyperglycemia produced by endogenous glucagon in streptozot-
ocin diabetic rats [30]. Herein, the partial effects of the antagonist
in attenuating the blood glucose level in the fasted state point to
the presence of other altered circulating factors that may act in
synergy with glucagon. Thus, hyperglucagonemia contributes to
the impaired glucose homeostasis of GC-treated rats despite their
markedly increased plasma insulin concentration.
Figure 4. The number of docked glucagon granules is increased in the a-cells of DEX rats. A: Electron micrographs of a-cells from CTL and
DEX rats. The images demonstrate an enlargement of the Golgi complex (GC) and the increase in glucagon granules docked to the plasma membrane
in the DEX a-cells (*). N, Nucleus; Mi, mitochondria. B: Profile of glucagon granules per median section of a-cells. C: Proportion of granules docked to
the plasma membrane of a-cells. Data are the mean 6 SEM (n= 16 cells in each condition). ** p,0.01 vs. CTL.
doi:10.1371/journal.pone.0093531.g004
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Figure 5. Glucagon stimulates insulin secretion in islets isolated from DEX rats. A: Insulin secretion in response to incubation with
5.6 mmol/l glucose with or without glucagon or forskolin in islets isolated from DEX and CTL rats (n= 10 wells). B: Representative immunoblots for
the glucagon receptor (GR) and b-actin and their quantification (bar graphs) for DEX and CTL islet lysates (n= 6 independent samples). Data are the
mean 6 SEM. * p,0.05, *** p,0.001 vs. CTL. {{{ p,0.001 vs. 5.6 m glucose. ``` p,0.001 vs. 5.6 mmol/l glucose plus 1 mmol/l glucagon in A. C:
Immunostaining of pancreas sections from DEX and CTL rats for the GR (green) and insulin or glucagon (red). Merged in orange. DAPI was used for
nuclei staining (n= 3 pancreases). Scale bars = 7.5 mm.
doi:10.1371/journal.pone.0093531.g005
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Glucagon secretion in response to high glucose concentrations
was not properly suppressed in the islets of DEX rats compared
with the controls. This phenomenon was not associated with
altered glucagon synthesis or direct effects of dexamethasone on a-
cells. In agreement with our findings, mice pretreated with
prednisolone show enhanced a-cell secretory activity in response
to arginine, which is not associated with changes in the islet
glucagon content or a direct effect of prednisolone [31]. It has
been proposed that glucagon hypersecretion in the presence of
high glucose concentrations, as in T2DM, may be associated with
a lower inhibitory effect of insulin on a-cells [32], impaired glucose
sensing by a-cells or malfunction of neural regulation [17] rather
than augmented a-cell expansion [16]. The fact that glucagon
release did not change in response to low, but did in response to
high glucose indicates that these values are primarily consequence
of impaired function. Interestingly, we found that in DEX rats, the
glucagon levels were higher under conditions of augmented blood
glucose levels and hyperinsulinemia. Notwithstanding, the amount
of a-cell mass may not be neglected in DEX rats, since the non-
significant increase (,51%) of the normalized a-cell mass may
contribute for the increased circulating glucagon levels. Mice
lacking microRNA-375 (375KO) share some characteristics with
our DEX rats (e.g., hyperglycemia, fast and fed hyperglucagon-
emia, glucose intolerance and reduced effect of glucose to inhibit
glucagon secretion) [33]. The authors associated the involvement
of a-cells with the disrupted glucose homeostasis based on the 29%
increase of the relative a-cell (no data regarding the absolute a-cell
mass was shown). Thus, several processes, whose molecular basis
merits further investigation, may contribute to excessive glucagon
release.
Numerous studies with mice [20], rats [21,34] and humans [26]
have reported the presence of functional glucagon receptors in b-
cells. Glucagon generates synergic signals in glucose-stimulated
insulin secretion (GSIS) [20,21] that involve the activation of
adenylyl cyclase and protein kinase A (PKA). Here, we observed
that islets from DEX rats secreted more insulin in response to
glucagon at basal glucose conditions compared with islets from
control rats. This insulin hypersecretion might be involved in the
marked 8.5-fold increase in the fasted plasma insulin values,
among other factors (e.g., highly islet insulin response to glucose)
[7]. This effect was only significant in the islets from the DEX rats
but not in the islets from the controls, which reinforces the role for
glucagon in b-cells in DEX rats. These findings point to an
apparent increase in glucagon sensitivity in the islets of DEX rats.
Consistent with this idea, the islets from DEX rats contained
higher levels of glucagon receptor. Additionally, forskolin, an
activator of adenylyl cyclase, was more potent in the islets from
DEX rats at 5.6 mmol/l glucose. Insulin secretion may also be
modulated by intra-islet GC metabolism. It was previously
demonstrated that the enzymatic activity of 11bHSD-1, which
generates active corticosterone from inactive 11-DHC, results in a
reduction in insulin secretion in vitro [28]. In in vivo conditions,
however, the adequate elevation of b-cell 11bHSD-1 activity is a
compensatory mechanism that prevents high-fat diet-induced b-
cell failure [35]. In addition, there is evidence that volunteers
treated with prednisolone for 6 consecutive days have increased
11bHSD-1 activity, as the administration of cortisone in these
individuals results in a marked rise in the serum cortisol level and
the cortisol/cortisone ratio [36]. Islets from DEX rats, but not
from control rats, secreted more insulin in response to 5.6 mmol/l
glucose in the presence of 11-DHC. While the elevation of
11bHSD-1 activity in the hepatic and adipose tissue leads to
disturbances in glucose metabolism, mimicking metabolic syn-
drome [37], our data indicate that, at least for islet function, intra-
islet GC metabolism may be involved in the compensatory insulin
Table 2. Insulin secretion ratio in isolated islets from CTL and
DEX rats.
CTL DEX
Glucagon/Glucose 1.660.2 2.360.2*
Forskolin/Glucose 3.260.7 3.560.5
The medium containing 1 mmol/l glucagon or 5 mmol/l forskolin also contained
5.6 mmol/l glucose. Data are expressed as mean 6 SEM (n= 10 wells).
* p,0.05 vs. CTL.
doi:10.1371/journal.pone.0093531.t002
Figure 6. 11-Dehydrocorticosterone [11-DHC) stimulates insu-
lin secretion under basal glucose conditions in islets isolated
from DEX rats. A: Insulin secretion in response to incubation with
5.6 mmol/l glucose with or without 11-DHC or carbenoxolone in islets
isolated from DEX and CTL rats (n= 10 wells). B: Insulin secretion in
response to incubation with 16.7 mmol/l glucose with or without 11-
DHC or carbenoxolone in islets isolated from DEX and CTL rats (n= 10
wells). Data are the mean 6 SEM. *** p,0.001 vs. CTL. { p,0.05 vs.
5.6 mmol/l glucose. ` p,0.05 vs. 5.6 mmol/l glucose plus 100 nmol/l
11-DHC.
doi:10.1371/journal.pone.0093531.g006
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hypersecretion that is required to face the GC-imposed IR in DEX
rats. These findings are consistent with previous observations [35].
In conclusion, treatment with high doses of GC induces
hyperglucagonemia, which disrupts glucose homeostasis. The
impairment of the a-cell response to inhibitory glucose signals
agrees with the increase in plasma glucagon, which, in parallel,
may contribute to the compensatory b-cell hypersecretion
resulting from GC therapy. Blockage of the glucagon receptor
seems to be effective in preventing GC-induced hyperglycemia
and represents a potential mechanism for the treatment of
hyperglycemia induced by GC treatment.
Supporting Information
Figure S1 Morphometric analysis of non-a cells. A:
Relative, B: absolute, and C: normalized non-a-cell mass in
DEX and CTL rats. Data are the mean 6 SEM (n = 6). * p,0.05
vs. CTL.
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